Key result
Immune checkpoint inhibitors carry high risk for severe, early-onset myocarditis requiring rapid intervention.
Why the study?
Patients with cancer have multiple etiological factors for myocarditis, including chemotherapy, radiation, immunotherapy, and infections, necessitating a comprehensive review.
Answers are grounded in this paper and cite their sources.
Clinicians must vigilantly monitor cancer patients for early ICI myocarditis given high lethality; review supports awareness but leaves prospective management trials open.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2022) conducted a review in Myocarditis in cancer patients. Antineoplastic therapies (including immune checkpoint inhibitors) was evaluated. Cancer therapies, particularly immune checkpoint inhibitors, can cause severe myocarditis characterized by early onset, high lethality, and a need for prompt diagnosis and management.
Synapse has enriched 10 related papers. Consider them for comparative context: